Research!America’s 22nd annual Advocacy Awards will pay a tribute to John Edward Porter, Research!America chair emeritus, for his decades-long commitment to advancing medical and health research. Porter served as a House member representing the 10th district in Illinois from 1980 to 2001, during which time he chaired the House Appropriations Subcommittee on Labor, HHS, Education, and Related Agencies.
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
